NO20061532L - Sammensetning og fremgangsmate til a fasilitere tilheling av ben - Google Patents

Sammensetning og fremgangsmate til a fasilitere tilheling av ben

Info

Publication number
NO20061532L
NO20061532L NO20061532A NO20061532A NO20061532L NO 20061532 L NO20061532 L NO 20061532L NO 20061532 A NO20061532 A NO 20061532A NO 20061532 A NO20061532 A NO 20061532A NO 20061532 L NO20061532 L NO 20061532L
Authority
NO
Norway
Prior art keywords
composition
magnesium
bone healing
green tea
tea extract
Prior art date
Application number
NO20061532A
Other languages
English (en)
Inventor
Matthias Rath
Vadim Ivanov
Shrirang Netke
Alexandra Niedzwiecki
Wahid M Roomi
Original Assignee
Matthias Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matthias Rath filed Critical Matthias Rath
Publication of NO20061532L publication Critical patent/NO20061532L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Den foreliggende oppfinnelse tilveiebringer en næringssammensetning som er effektiv til å fasilitere bentilheling hos mennesker, som omfatter lysin, prolin, askorbinsyre, kopper, vitamin B6. Næringssammensetningen inneholder 27-34 vekt% lysin, 14-16 vekt% prolin og 42-47 vekt% askorbinsyre. Næringssammensetningen omfatter ytterligere vitamin A, vitamin D3, vitamin E, vitamin B1, vitamin B2, niacin, folsyre, vitamin B12, biotin, pantotensyre, kalsium, fosfor, magnesium, sink, selen, mangan, krom, molybden, kalium, sitrusfruktskallbioflavanoider, arginin, cystein, inositol, karnitin, koenzym Q10, og pyknogenol. Den foreliggende oppfinnelse angår også anvendelser av næringssammensetningene hos mennesker for å fasilitere bentilheling.
NO20061532A 2003-09-05 2006-04-04 Sammensetning og fremgangsmate til a fasilitere tilheling av ben NO20061532L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/657,019 US20050053673A1 (en) 2003-09-05 2003-09-05 Composition and method for facilitating bone healing
PCT/EP2004/006841 WO2005023020A1 (en) 2003-09-05 2004-06-24 Composition and method for facilitating bone healing

Publications (1)

Publication Number Publication Date
NO20061532L true NO20061532L (no) 2006-04-04

Family

ID=34226477

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20061461A NO20061461L (no) 2003-09-05 2006-03-31 Farmasoytisk sammensetning som blant annet omfatter vitamin C, magnesium og ekstrakt av gronn te for hemming av hjertekarsykdommer
NO20061532A NO20061532L (no) 2003-09-05 2006-04-04 Sammensetning og fremgangsmate til a fasilitere tilheling av ben

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20061461A NO20061461L (no) 2003-09-05 2006-03-31 Farmasoytisk sammensetning som blant annet omfatter vitamin C, magnesium og ekstrakt av gronn te for hemming av hjertekarsykdommer

Country Status (20)

Country Link
US (4) US20050053673A1 (no)
EP (1) EP1662908B9 (no)
JP (1) JP2007504182A (no)
KR (1) KR20060069851A (no)
CN (2) CN1845683A (no)
AT (1) ATE458478T1 (no)
AU (1) AU2004269867A1 (no)
BR (1) BRPI0414076A (no)
CA (1) CA2532941A1 (no)
DE (2) DE602004022060D1 (no)
ES (2) ES2330111T3 (no)
IL (2) IL173159A0 (no)
MX (1) MXPA06002526A (no)
NO (2) NO20061461L (no)
PL (1) PL1662908T3 (no)
RS (2) RS20060150A (no)
RU (1) RU2006110949A (no)
UA (1) UA81973C2 (no)
WO (2) WO2005023020A1 (no)
ZA (2) ZA200601214B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7901873B2 (en) * 2001-04-23 2011-03-08 Tcp Innovations Limited Methods for the diagnosis and treatment of bone disorders
US8377904B2 (en) 2004-02-09 2013-02-19 Hill's Pet Nutrition, Inc. Composition and method for use in cartilage affecting conditions
BRPI0616866A8 (pt) * 2005-10-06 2018-07-31 Nestec Sa Enterococos probióticos para melhorar a imunidade
EP1862163A1 (de) * 2006-05-12 2007-12-05 Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG L-Carnitin zur Kristallisationsverzögerung
US20080031869A1 (en) * 2006-08-02 2008-02-07 Fontaine Juliette S Pain relief composition
WO2008139314A1 (en) * 2007-05-11 2008-11-20 Horphag Research (Luxembourg) Holding Sa Compositions and methods for treating joint disorders
US20090060879A1 (en) * 2007-09-04 2009-03-05 The Procter & Gamble Company Oral Compositions, Products and Methods Of Use
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
EP2257300B1 (en) * 2008-01-28 2014-08-27 Beauty Pearl Group Limited Formulas comprising calcium, magnesium, zinc, and vitamin d3 for the prevention and amelioration of osteoporosis
IT1397522B1 (it) 2009-12-21 2013-01-16 Solartium Entpr Ltd Uso di una combinazione per il trattamento dell'osteoartrosi
BE1019135A5 (nl) * 2010-01-08 2012-03-06 Lab Smeets Nv Voedingssupplement bevattende glucosamine.
KR20130140100A (ko) * 2010-12-09 2013-12-23 씨그마-토 인더스트리에 파마슈티체 리유니테 에스. 피. 에이. 피부 장애 치료용 국소 사용을 위한 조성물
US12612370B2 (en) 2011-03-02 2026-04-28 Thermolife International, Llc Amino acid compositions
HUE032165T2 (en) 2011-04-13 2017-09-28 Thermolife Int Llc Methods of using N-actyl-beta-alanine
WO2013108263A1 (en) 2012-01-18 2013-07-25 Zota Health Care Ltd Pharmaceutical formulation to reduce inflammation of bones and joint friction with improved cartilage quality
US20160081959A1 (en) * 2014-09-24 2016-03-24 Glanbia Plc Method of using arginine silicate inositol complex for wound healing or repair
JP6211558B2 (ja) * 2015-05-14 2017-10-11 株式会社東洋新薬 美容組成物
JP6906248B2 (ja) * 2017-06-15 2021-07-21 株式会社東洋新薬 美容組成物
JP6608874B2 (ja) * 2017-06-15 2019-11-20 株式会社東洋新薬 美容組成物
US10004757B1 (en) 2017-09-22 2018-06-26 Nutri Vida, LLC Oral supplement
US20190175533A1 (en) * 2017-12-12 2019-06-13 Pharmco International Inc. Nutritional supplement for improved calcium absorption
JP7098198B2 (ja) * 2019-10-08 2022-07-11 株式会社東洋新薬 美容組成物
IT202000009700A1 (it) * 2020-05-04 2021-11-04 Parthenogen Sagl Combinazione di micronutrienti per stimolare la produzione endogena di sulfide di idrogeno (h2s)
CN111529709A (zh) * 2020-06-03 2020-08-14 北京易思腾翻译服务有限公司 一种可用于体重控制且可逆转动脉粥样硬化的组合物
AU2021377897A1 (en) 2020-11-12 2024-09-12 Thermolife International, Llc Methods of increasing blood oxygen saturation
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches
KR20230145103A (ko) 2021-02-11 2023-10-17 써모라이프 인터내셔널, 엘엘씨 산화질소 기체의 투여 방법
CA3219195A1 (en) * 2021-06-03 2022-12-08 Magle Chemoswed Ab A pharmaceutically acceptable aqueous gel composition for mrna delivery
US20230293618A1 (en) * 2022-02-11 2023-09-21 Jessica Karns Compositions comprising orange peel derivatives and dicalcium phosphate and methods of using
CN114560924B (zh) * 2022-02-21 2023-06-20 华南理工大学 一种促进成骨细胞分化的含硒特立帕肽和融合多肽及其应用
US12029726B1 (en) * 2023-07-06 2024-07-09 Matthias W. Rath Composition and method of treating conditions associated with extracellular matrix dysfunction by administering micronutrient composition
WO2026073932A1 (en) * 2024-10-01 2026-04-09 Société des Produits Nestlé S.A. Compositions containing vitamin b6 and nicotinamide and methods of using such compositions for use in promoting bone growth

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3405120A (en) * 1966-01-27 1968-10-08 Green Cross Corp Low molecular chondroitin sulfate and method for manufacturing the same
SU1268169A1 (ru) * 1979-12-17 1986-11-07 Актюбинский государственный медицинский институт Способ лечени переломов костей
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
US5232709A (en) * 1990-08-06 1993-08-03 The Procter & Gamble Company Calcium and trace mineral supplements comprising estrogen
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US6440446B1 (en) * 1998-04-22 2002-08-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent for anti-osteoporosis
JP2000063284A (ja) * 1998-08-21 2000-02-29 Terumo Corp 炎症性腸疾患再燃防止剤
US6914073B2 (en) * 1999-03-18 2005-07-05 Bristol Myers Squibb Company Vitamin formulation for cardiovascular health
US6528042B1 (en) * 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US7235237B2 (en) * 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
US6579544B1 (en) * 2000-05-31 2003-06-17 Nutriex, L.L.C. Method for supplementing the diet
UA77660C2 (en) * 2000-10-03 2007-01-15 Compositions and methods for reducing plasma lipoprotein a level in human
ES2261136T3 (es) * 2000-10-09 2006-11-16 Matthias Dr. Med. Rath Composicion terapeutica de ascorbato con lisina y arginina para prevencion y tratamiento del cancer.
JP2003061631A (ja) * 2001-08-28 2003-03-04 Takaaki Morikawa クエン酸とアミノ酸を主成分とした粉末飲料及び食品。
DE20207569U1 (de) * 2002-05-14 2002-12-05 Kyberg Pharma Vertriebs-GmbH & Co. KG, 82041 Oberhaching Diätetische und pharmazeutische Zusammensetzungen
US6551629B1 (en) * 2002-07-03 2003-04-22 Vitacost.Com, Inc. Cardiovascular promotion and maintenance composition
CN1234371C (zh) * 2003-01-28 2006-01-04 马驷 纳米铜粉作为制备预防治疗骨质疏松、骨折药物的应用

Also Published As

Publication number Publication date
US20070166400A1 (en) 2007-07-19
BRPI0414076A (pt) 2006-10-24
WO2005023020A1 (en) 2005-03-17
ATE458478T1 (de) 2010-03-15
PL1662908T3 (pl) 2009-12-31
DE602004025728D1 (de) 2010-04-08
US20070122399A1 (en) 2007-05-31
RS20060150A (sr) 2007-12-31
UA81973C2 (uk) 2008-02-25
IL173159A0 (en) 2006-06-11
CA2532941A1 (en) 2005-03-17
DE602004022060D1 (de) 2009-08-27
RU2006110949A (ru) 2007-10-10
EP1662908B9 (en) 2010-09-01
AU2004269867A1 (en) 2005-03-17
RS20060149A (sr) 2008-04-04
EP1662908B1 (en) 2009-07-15
CN1845683A (zh) 2006-10-11
EP1662908A1 (en) 2006-06-07
JP2007504182A (ja) 2007-03-01
US20050053674A1 (en) 2005-03-10
ES2330111T3 (es) 2009-12-04
ES2341717T3 (es) 2010-06-25
ZA200407064B (en) 2005-05-11
WO2005025589A1 (en) 2005-03-24
IL173257A0 (en) 2006-06-11
NO20061461L (no) 2006-03-31
US20050053673A1 (en) 2005-03-10
MXPA06002526A (es) 2006-06-20
KR20060069851A (ko) 2006-06-22
ZA200601214B (en) 2007-04-25
CN1845729A (zh) 2006-10-11

Similar Documents

Publication Publication Date Title
IL173257A0 (en) Composition and method for facilitating bone healing
WO2004110383A3 (en) Pharmaceutical composition and method for alleviating side effects of estrogen replacement therapy
WO2004032827A3 (en) Hepatitis c virus inhibitors
AU2003248535A1 (en) Heterocyclicsulfonamide hepatitis c virus inhibitors
WO2003041649A3 (en) Cyanoalkylamino derivatives as protease inhibitors
WO2002060926A3 (en) Hepatitis c tripeptide inhibitors
CA2473070A1 (en) Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
WO2004043339A3 (en) Substituted cycloalkyl p1' hepatitis c virus inhibitors
WO2006017295A3 (en) Tetrapeptide analogs
IL183607A0 (en) Composition for proteasome inhibition
WO2007147128A3 (en) Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
WO2005063742A3 (en) Amidino compounds as cysteine protease inhibitors
BRPI0414072A (pt) composição farmacêutica e seus usos para o retardo de doenças cardiovasculares
IS6676A (is) Amínóalkenýlbensóýl-bensófúran eða bensóþíófenafleiður, aðferð til framleiðslu þeirra og samsetningar sem innihalda þær
TW200505872A (en) Hepatitis C virus inhibitors
UA89046C2 (ru) Производные бензогидроазепинов, фармацевтическая композиция и способ лечения сердечно-сосудистых заболеваний
AU2003227008A1 (en) 2-methylthiazolidine-2,4-dicarboxylic acid and the salts thereof used for the treatment of neurodegenerative diseases
EA200501677A2 (ru) Фосфонатсодержащие противораковые соединения (варианты), фармацевтическая композиция (варинты) и лекарственная форма на их основе, способ лечения рака (варианты) и способ подавления неопластических заболеваний (варианты)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application